Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VentiRx Pharmaceuticals, a biopharmaceutical company, has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services both in Scottsdale, Arizona.
Subscribe to our email newsletter
The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.
VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer.
Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology.
Michael Kamdar, chief business officer of VentiRx, said: “We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic. This represents a significant milestone for VentiRx and our Toll-Like Receptor efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer.”